NASDAQ:PBLS Parabilis Medicines (PBLS) Stock Price, News & Analysis $33.31 -4.86 (-12.73%) As of 09/23/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Parabilis Medicines Stock (NASDAQ:PBLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Parabilis Medicines alerts:Sign Up Key Stats Today's Range$32.95▼$37.8950-Day Range$27.31▼$41.7352-Week Range$24.51▼$42.49Volume1.11 million shsAverage Volume1.01 million shsMarket Capitalization$4.11 billionP/E RatioN/ADividend YieldN/APrice Target$41.67Consensus RatingModerate Buy Company Overview Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass. Read More Parabilis Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScorePBLS MarketRank™: Parabilis Medicines scored higher than 68% of companies evaluated by MarketBeat, and ranked 224th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingParabilis Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialParabilis Medicines has a consensus price target of $41.67, representing about 25.1% upside from its current price of $33.31.Amount of Analyst CoverageParabilis Medicines has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Parabilis Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Parabilis Medicines are expected to grow in the coming year, from ($2.05) to ($1.60) per share. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.47% of the float of Parabilis Medicines has been sold short.Short Interest Ratio / Days to CoverParabilis Medicines has a short interest ratio ("days to cover") of 14.2, which indicates bearish sentiment.Change versus previous monthShort interest in Parabilis Medicines has recently increased by 4.96%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldParabilis Medicines does not currently pay a dividend.Dividend GrowthParabilis Medicines does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.38 News SentimentParabilis Medicines has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Parabilis Medicines this week, compared to 3 articles on an average week.Search Interest2 people have searched for PBLS on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Parabilis Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Parabilis Medicines insiders have not sold or bought any company stock.Percentage Held by InstitutionsParabilis Medicines has minimal institutional ownership at this time.Read more about Parabilis Medicines' insider trading history. Receive PBLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Parabilis Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBLS Stock News HeadlinesParabilis Medicines Inc (PBLS)September 23 at 12:34 AM | investing.comParabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 20, 2026 | americanbankingnews.comShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.September 24 at 1:00 AM | Digest Publishing (Ad)Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comParabilis Medicines Inc PBLSSeptember 10, 2026 | morningstar.comMParabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 1, 2026 | globenewswire.comParabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of DirectorsAugust 25, 2026 | markets.businessinsider.comParabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.August 25, 2026 | globenewswire.comSee More Headlines PBLS Stock Analysis - Frequently Asked Questions How have PBLS shares performed this year? Parabilis Medicines' stock was trading at $31.60 on June 10, 2026. Since then, PBLS stock has increased by 5.4% and is now trading at $33.31. How were Parabilis Medicines' earnings last quarter? Parabilis Medicines, Inc. (NASDAQ:PBLS) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.16) by $2.16. The firm earned $0.15 million during the quarter. When did Parabilis Medicines IPO? Parabilis Medicines (PBLS) raised $603 million in an initial public offering on Wednesday, June 10th 2026. The company issued 33,500,000 shares at $17.00-$19.00 per share. Who are Parabilis Medicines' major shareholders? Parabilis Medicines' top institutional investors include ARCH Venture Management LLC (5.43%), venBio Partners LLC (4.46%), Alphabet Inc. (4.16%) and Regeneron Pharmaceuticals Inc. (3.53%). View institutional ownership trends. How do I buy shares of Parabilis Medicines? Shares of PBLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PBLS CIK1657677 Webparabilismed.com Phone617-945-9510FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Price Target for Parabilis Medicines$41.67 High Price Target$45.00 Low Price Target$40.00 Potential Upside/Downside+25.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares123,530,000Free FloatN/AMarket Cap$4.11 billion OptionableN/A BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:PBLS) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Parabilis Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Parabilis Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
